Tags

Type your tag names separated by a space and hit enter

Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients.
Circulation. 2003 Nov 18; 108(20):2467-72.Circ

Abstract

BACKGROUND

Low-density lipoprotein (LDL) can be oxidatively modified by reactive oxygen species, thus generating oxLDL. The latter induce formation of specific antibodies (oxLDLAb), which are detectable in patients with atherosclerosis, in which they might play a pathogenic or a protective role. Thus, we aimed to investigate the association of antibodies with oxidized LDLs (oxLDL) (oxLDLAbs) with coronary artery disease (CAD) and acute coronary syndromes.

METHODS AND RESULTS

In a cross-sectional study of 529 consecutive patients undergoing quantitative coronary angiography for suspected CAD, we measured the titer of IgG oxLDLAbs by ELISA. With regression analysis techniques, we also investigated the determinants of oxLDLAb titer and the association of oxLDLAbs with CAD severity. We found no significant differences of oxLDLAb titer between groups of patients without and with different CAD severity. The oxLDLAb titer was 18.6 enzyme units (EU) (11.5 to 25.7 EU/mL) (mean, 95% CI) in patients without CAD; 16.8 EU (9.6 to 24.2 EU) in patients with stenosis <50%; and 19.9 EU (15 to 24.8 EU), 17.2 (13.8 to 20.6 EU), and 14.7 EU (12.1 to 17.3 EU) in those with in 1-, 2-, or 3-vessel > or =50% stenosis, respectively. Similarly, no differences of oxLDLAb titer between patients without and with acute coronary syndrome were found. The oxLDLAb titer correlated weakly with aging and with serum total, LDL, and HDL cholesterol and plasma homocysteine levels; however, only age and HDL cholesterol remained significant predictors of the oxLDLAb titer at a stepwise regression analysis.

CONCLUSIONS

The results of this study, which was adequately powered from the statistical standpoint, provided no evidence for an association of IgG oxLDLAb titer with angiographically assessed CAD in whites.

Authors+Show Affiliations

Department of Clinical and Experimental Medicine, Clinica Medica 4, University Hospital, University of Padova, Italy. gianpaolo.rossi@unipd.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14581399

Citation

Rossi, Gian Paolo, et al. "Antibodies to Oxidized Low-density Lipoproteins and Angiographically Assessed Coronary Artery Disease in White Patients." Circulation, vol. 108, no. 20, 2003, pp. 2467-72.
Rossi GP, Cesari M, De Toni R, et al. Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation. 2003;108(20):2467-72.
Rossi, G. P., Cesari, M., De Toni, R., Zanchetta, M., Maiolino, G., Pedon, L., Ganzaroli, C., Maiolino, P., & Pessina, A. C. (2003). Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation, 108(20), 2467-72.
Rossi GP, et al. Antibodies to Oxidized Low-density Lipoproteins and Angiographically Assessed Coronary Artery Disease in White Patients. Circulation. 2003 Nov 18;108(20):2467-72. PubMed PMID: 14581399.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. AU - Rossi,Gian Paolo, AU - Cesari,Maurizio, AU - De Toni,Renzo, AU - Zanchetta,Mario, AU - Maiolino,Giuseppe, AU - Pedon,Luigi, AU - Ganzaroli,Chiara, AU - Maiolino,Pietro, AU - Pessina,Achille C, Y1 - 2003/10/27/ PY - 2003/10/29/pubmed PY - 2003/12/24/medline PY - 2003/10/29/entrez SP - 2467 EP - 72 JF - Circulation JO - Circulation VL - 108 IS - 20 N2 - BACKGROUND: Low-density lipoprotein (LDL) can be oxidatively modified by reactive oxygen species, thus generating oxLDL. The latter induce formation of specific antibodies (oxLDLAb), which are detectable in patients with atherosclerosis, in which they might play a pathogenic or a protective role. Thus, we aimed to investigate the association of antibodies with oxidized LDLs (oxLDL) (oxLDLAbs) with coronary artery disease (CAD) and acute coronary syndromes. METHODS AND RESULTS: In a cross-sectional study of 529 consecutive patients undergoing quantitative coronary angiography for suspected CAD, we measured the titer of IgG oxLDLAbs by ELISA. With regression analysis techniques, we also investigated the determinants of oxLDLAb titer and the association of oxLDLAbs with CAD severity. We found no significant differences of oxLDLAb titer between groups of patients without and with different CAD severity. The oxLDLAb titer was 18.6 enzyme units (EU) (11.5 to 25.7 EU/mL) (mean, 95% CI) in patients without CAD; 16.8 EU (9.6 to 24.2 EU) in patients with stenosis <50%; and 19.9 EU (15 to 24.8 EU), 17.2 (13.8 to 20.6 EU), and 14.7 EU (12.1 to 17.3 EU) in those with in 1-, 2-, or 3-vessel > or =50% stenosis, respectively. Similarly, no differences of oxLDLAb titer between patients without and with acute coronary syndrome were found. The oxLDLAb titer correlated weakly with aging and with serum total, LDL, and HDL cholesterol and plasma homocysteine levels; however, only age and HDL cholesterol remained significant predictors of the oxLDLAb titer at a stepwise regression analysis. CONCLUSIONS: The results of this study, which was adequately powered from the statistical standpoint, provided no evidence for an association of IgG oxLDLAb titer with angiographically assessed CAD in whites. SN - 1524-4539 UR - https://www.unboundmedicine.com/medline/citation/14581399/Antibodies_to_oxidized_low_density_lipoproteins_and_angiographically_assessed_coronary_artery_disease_in_white_patients_ L2 - http://www.ahajournals.org/doi/full/10.1161/01.CIR.0000097122.19430.48?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -